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Abstract
Purpose—To investigate the hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs)
lower lung cancer risk.
Methods—We analysed pooled individual-level data from seven case–control and one cohort
study in the International Lung Cancer Consortium (ILCCO). Relative risks for lung cancer
associated with self-reported history of aspirin and other NSAID use were estimated within
individual studies using logistic regression or proportional hazards models, adjusted for packyears
of smoking, age, calendar period, ethnicity and education and were combined using random
effects meta-analysis.
Results—A total of 4,309 lung cancer cases (mean age at diagnosis 65 years, 45%
adenocarcinoma and 22% squamous-cell carcinoma) and 58,301 non-cases/controls were
included. Amongst controls, 34% had used NSAIDs in the past (81% of them used aspirin). After
adjustment for negative confounding by smoking, ever-NSAID use (affirmative answer to the
study-specific question on NSAID use) was associated with a 26% reduction (95% confidence
interval 8 to 41%) in lung cancer risk in men, but not in women (3% increase (−11% to 30%)). In
men, the association was stronger in current and former smokers, and for squamous-cell
carcinoma than for adenocarcinomas, but there was no trend with duration of use. No differences
were found in the effects on lung cancer risk of aspirin and non-aspirin NSAIDs.
Conclusions—Evidence from ILCCO suggests that NSAID use in men confers a modest
protection for lung cancer, especially amongst ever-smokers. Additional investigation is needed
regarding the possible effects of age, duration, dose and type of NSAID and whether effect
modification by smoking status or sex exists.
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Introduction
Worldwide, lung cancer is the leading cause of cancer mortality in men (∼951,000 deaths in
2008) and the second leading cause in women (427,000 deaths) [1,2]. Whilst tobacco control
dominates strategies to reduce this burden, chemoprevention may also contribute, especially
amongst former smokers. Aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) may have anti-cancer properties, especially for cancers whose aetiology
implicates the role of chronic inflammation, such as colorectal and lung. The anti-
inflammatory effect of NSAIDs operates through inhibition of prostaglandins via
suppression of cyclooxygenase-1 (COX-1) and COX-2, targeting the arachidonic acid
metabolic pathway. Non-small-cell lung cancers in particular overexpress COX-2 [3, 4].
Aspirin reduces risk of adenocarcinoma of the colon, as demonstrated in randomised
controlled trials (RCTs) [5, 6], an effect that may be restricted to COX-2 tumours [7]. In
2011, Rothwell et al. pooled data from 8 double-blind RCTs of daily aspirin in which the
median scheduled treatment time was at least 4 years and analysed the effect of aspirin on
cancer mortality as secondary endpoints (primary endpoints were cardiovascular diseases)
[8]. Overall cancer mortality rates were 22% lower (95% CI: 13, 30) in those randomised to
the aspirin group compared to the control group, and lung cancer-specific mortality rates
were reduced by 29% (95% CI: 11, 42) in the aspirin group in the 20-year period after the
trial commenced. No significant effect on lung cancer was observed in the initial 5-year
period after randomisation (reduction of 8% (95% CI: −30, 35)). No trend with dose (above
75 mg/day) was observed, but the effect on all cancers was stronger in adenocarcinomas and
increased with longer durations of treatment and was present in both smokers and non-
smokers. The authors suggest that their intention-to-treat analyses were likely to have been
conservative, as about 40% of patients in the aspirin group had stopped treatment by the end
of the trial period.
Other studies of NSAIDs and lung cancer incidence or mortality have been observational in
nature (over 15 published studies). A 2005 meta-analysis by Khuder et al. summarised
evidence at the time and found that after adjusting for smoking, NSAIDs were associated
with a RR of 0.68 (95% CI: 0.55, 0.85), stronger for small-cell than non-small-cell lung
cancer although only two studies were able to stratify by histology [9]. As found in the
meta-analysis, in settings where smokers are more likely to be prescribed aspirin for cardio-
prevention—today common practice—confounding by smoking would lead to an
underestimation of any real protective effect of NSAIDs; thus, accurate detailed smoking
data are crucial in observational studies. Several further observational studies have been
published, with variable findings including one null association [10], a protective effect of
aspirin for non-small-cell lung cancer in women (men were not included) [11], the VITamin
and Lifestyle cohort found a protective effect of NSAIDs in men, but not women, and for
adeno-carcinomas and not squamous-cell carcinomas [12], a suggestion of a protective
effect of low-dose aspirin in the Women's Health Study [13], and a protective effect of non-
aspirin NSAIDs and not aspirin using UK GP prescription records [14], but no clear
evidence of an effect in the Nurses' Health Study [15].
Thus, several uncertainties remain concerning whether the effects of aspirin and non-aspirin
NSAIDs are equal in reducing lung cancer incidence, what lung cancer histologies are
affected and whether there is effect modification by gender or smoking status. We
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investigated these associations using pooled individual-level data from the International
Lung Cancer Consortium (ILCCO), for which there were over 4,000 cases with data on
NSAID use.
Materials and methods
ILCCO was established in 2004 with the aims to share comparable data and maximise
resource saving for lung cancer epidemiology research. Full details have been provided
previously [16] and are available at http://ilcco.iarc.fr. For the current investigation, we
included 8 studies from ILCCO that had data on aspirin or NSAID use prior to diagnosis,
including American Health Foundation Tobacco Study (AHFTS) [17], New England Lung
Cancer study (NELCS) [18], Danish Diet Cancer and Health Study (DDCHS) [19],
Memorial Sloan-Kettering Cancer Center (MSKCC) study of never smokers and studies in
Hawaii [20], Moffitt Cancer Center [21], Harvard [22] and the National Israel Cancer
Control Center (NICCC) lung cancer study (Table 1). All 8 studies were approved by local
ethical review boards. Six of the 8 studies were conducted in the US; all but one (DDCHS)
had case–control designs with NSAID use recalled at the time of diagnosis/interview in
cases/controls. DDCHS was a cohort study, in which self-reported NSAID use was collected
in a baseline questionnaire, a median of 7 years prior to lung cancer diagnosis in cases. In
the Harvard study, a question on NSAIDs was included from 2005 onwards; thus, only study
participants recruited thereafter were included. In AHFTS, subjects interviewed between 1st
January 1992 and 30th April 1997 (when NSAIDs were ascertained) were included, and as
this was the only study where controls were hospital-based patients including some cancer
patients, we excluded controls whose hospital admission was due to cancer or a condition
for which aspirin is either prescribed (e.g. rheumatoid and osteoarthritis, cardiovascular
conditions, migraine, general pain relief and possibly colorectal cancer) or contraindicated
(e.g. peptic ulcers).
The questions asked pertaining to previous NSAID or aspirin use varied between studies
(Table 1). All questions related to having taken any NSAIDs (i.e. prescription and non-
prescription use), except the Moffitt study where the question referred to ever having been
prescribed aspirin or ibuprofen. The specified minimum duration and intensity (times/week)
of use varied between studies. Lifetime NSAID use was ascertained, except in the
prospective DDCHS study in which participants were questioned about use in the year prior
to the baseline questionnaire.
Individual-level data from each contributing study were pooled. For NSAID and aspirin use,
study-specific variables were obtained, from which we coded each listed drug as aspirin
(any drug containing acetylsalicylic acid), or non-aspirin NSAIDs, with the help of the US
Food and Drug Administration Drugs@FDA online database that can be searched both by
drug name and active ingredient. Non-aspirin NSAIDs included ibuprofen, naproxen,
sulindac, indomethacin and diclofenac amongst others. We then generated, for both total
NSAID and aspirin use, common variables pertaining to ‘ever use’, and where possible, total
duration of use, age at first and last use, and average number of pills per week. We also
extracted the predominant reason for use (taken as the reason pertaining to the longest
period for subjects with multiple drug-use periods with different reasons). Finally, we
explored whether any observed effect of NSAIDs/aspirin was likely to be drug specific or
due to residual confounding by factors associated with use of pain relievers in general. To
do this as a control measure, we also analysed the effect of acetaminophen, another common
non-NSAID pain relief medication (where available within studies).
Variables for well-established lung cancer risk factors and participant characteristics were
harmonised across studies. The variable ‘ever-use of NSAIDs’ indicates an affirmative
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answer to the question(s) asked based on the study-specific definition (as each study defined
‘ever use’ based on different minimum duration and frequency of NSAID use). For
smoking, we created variables pertaining to smoking status as self-reported at the time of
diagnosis/interview in cases/non-cases: never smokers (<100 cigarettes over lifetime), ex-
smoker (stopped smoking at least 2 years previously) and current smokers (smoked within
the past 2 years). For current and ex-smokers, smoking pack years were calculated as the
intensity of smoking (packs per day) multiplied by years of smoking at that intensity,
summed over all periods of smoking. Note that in DDCHS cohort, smoking data refer to
exposures up to the baseline questionnaire, and updated smoking information was not
obtained during follow-up.
Statistical methods
A two-stage approach to the analysis was taken: stage 1 being a within-study analysis and
stage 2 combining study-specific effects across all studies. In the first stage, the relative risk
(RR) for lung cancer associated with NSAID (or aspirin) use (or its characteristics) was
estimated in each study as odds ratios (OR) from logistic regression models for case–control
studies and conditional logistic regression for the Hawaiian matched case–control study. The
prospective DDCHS study was analysed using a proportional hazards model in which RRs
for time to first of lung cancer diagnosis/death/censoring, using age as the time-scale were
estimated by hazard ratios.
The second stage involved combining study-specific estimates using meta-analytic random
effects models, where between-study heterogeneity was examined using q-statistics and I2
values. These two stages were carried out for different levels of adjustment, beginning with
minimal adjustment for age and sex, thereafter additionally adjusting for smoking status
(current, ex (stopped smoking at least 2 years previously), never (less than 100 cigarettes
ever-smoked)), smoking pack years (continuous), educational level and ethnicity. Sub-group
analyses were also carried out by sex, histology (overexpression of COX-2 has been
reported particularly in adenocarcinomas and not for small or squamous-cell carcinoma),
age, smoking status and in subjects without a self-reported history of asthma (asthma is a
counter-indication for aspirin use [23], and it is not known whether asthma may be
associated with increased lung cancer risk). For the analysis of non-asthmatics in DDCHS,
previous diagnosis of asthma was included as a time-varying exposure; thus, subjects were
included in the non-asthma group up until the age at asthma diagnosis, if any. All analyses
were conducted in Stata version 11.
Results
The pooled data from the 8 studies totalled 4,309 cases and 58,301 non-cases/controls.
Amongst cases, mean age at lung cancer diagnosis was 65 years (inter-quartile range, 59–71
years), 49% were current smokers at the time of diagnosis and 36% were ex-smokers (Table
2). The most common histological types were adenocarcinomas (35%), squamous-cell
carcinomas (25%) and small-cell carcinomas (16%) in current smokers; in ex- and never-
smokers, there was a higher percentage of adenocarcinomas (52 and 72%, respectively) and
less squamous-cell lung carcinomas (21 and 5%, data not shown in tables).
Self-reported history of NSAID use by study and case/control status is shown in Table 3.
For both cases and controls, the percentage of NSAID use varied between studies, generally
increasing over calendar time from ∼30% in AHFTS to over 50% in the more recent
studies. At MSKCC, there was a particularly high proportion at 86%, but the NSAID
question did not specify a minimum duration or intensity of use. The prevalence of ever-use
of NSAIDs in cases versus controls was lower in 4 studies, similar in 2 and higher in 2
studies (Table 3). Where data were available (4 studies), mean age at first NSAID use was
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47.4, 56.2, 54.3 and 50.9 years in AHFTS, Florida, Hawaii and NELCS controls,
respectively, and median duration of use ranged from 5 to 10 years between studies. The
most common reasons for NSAID use, available in 3 studies, were cardioprotection, pain/
headache and rheumatic diseases (Table 3), with use for cardioprotection generally more
common in the later studies (amongst male controls, 68% in NELCS, 27% in Florida and
41% in AHFTS) and lower in women than in men (corresponding percentages in women:
46, 32 and 13%, respectively). Across all studies, the predominant type of NSAID used was
aspirin: between 76 and 92% of male NSAID users were also aspirin users, whilst this
percentage was lower in women (between 62 and 88%). Cardiovascular disease prevention
was a more common reason for aspirin use than it was for any NSAID use (data not shown).
Given the known associations of smoking, age, education and ethnicity with lung cancer,
and plausible association of each of these factors with NSAID use, they were considered as
potential confounders. Their associations with the odds of having taken NSAIDs were
examined amongst controls in each study, and patterns of use were broadly similar across
studies (except for MSKCC, see online supplementary table), with NSAID use being almost
twofold more likely in men than in women (the percentage of controls who had used
NSAIDs was 7.3% higher (95% CI: 3.8, 10.9) in men than in women in all studies excluding
DDCHS where it was 9.6% higher in women (8.7, 10.3)), at older ages and in current and
ex-smokers compared to never smokers (associations mutually adjusted for age, sex,
smoking status, education and ethnicity). The only exceptions to this were amongst women
in DDCHS and in the earlier AHFTS study in which use declined with age as it did in all
AHFTS controls.
For the association of ever-use of NSAIDs and lung cancer, there was strong evidence of sex
differences (p = 0.003 test for heterogeneity); thus, sex-specific results are presented from
here on. In men, the age-adjusted combined association was suggestive of a protective effect
with a 20% lower lung cancer risk (95% CI: 7, 32) associated with ever-use of NSAIDs
(data not shown). Negative confounding by smoking was present within studies and thus
additionally adjusting for smoking (current, never, ex), pack years of smoking, ethnicity and
education strengthened this association to a combined estimate of 26% lower risk (95% CI:
8, 41) (Fig. 1). Hereafter, all estimates are adjusted for these factors. Although between-
study heterogeneity was present for men (p = 0.06, Fig. 1), all but one study-specific point
estimate were below the null value of 1. NICCC was the study contributing to the greatest
heterogeneity (having the lowest odds ratio of 0.40), and in sensitivity analyses, removing
this study gave an overall relative risk that was only slightly smaller in magnitude, with a
risk reduction of 19% (95% CI: 4, 32) and there was no remaining heterogeneity (p = 0.29).
In contrast, for women the combined relative risk, both before (data not shown) and after
adjustment for smoking, was consistent with no association between NSAID use and lung
cancer risk, with a RR of 1.07 (95% CI: 0.94, 1.25), and study-specific estimates were not
significantly heterogeneous (Fig. 1). For analyses in both men and women, the DDCHS
study had the largest statistical weight in the meta-analysis: weights of 23.3% in men and
49% in women (larger in women because of the higher prevalence of NSAID use amongst
women in DDCHS). However, sensitivity analyses removing DDCHS did not change
overall estimates.
Associations of ever-use of aspirin (prevalence 28%, i.e. with or without use of other non-
aspirin NSAIDs) and of non-aspirin NSAID use exclusively (6.6% across studies) with lung
cancer were very similar (Table 4). In men, relative risk point estimates were 0.73 and 0.76
for aspirin and non-aspirin NSAIDs, respectively, and in women, there were null
associations for both. Thus, in further analyses, we focus on use of all types of NSAIDs
together. Furthermore, although there was heterogeneity in the definition of ever-NSAID use
(see Methods section), individual exclusion of each study did not change the point estimate.
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(In Table 4, although MSKCC appears to be an outlier, the statistical weight contribution of
this small study was <3%, thus, it did not greatly influence the combined estimate and was
not excluded.)
Duration of NSAID use was available in 5 studies. Amongst NSAID users, in individual
studies between 27 and 52% of men had taken NSAIDs for at least 10 years, and durations
were similar amongst female NSAID users (corresponding range, 25–49%). In men, NSAID
users of less than 5 years use had a 21% risk reduction (95% CI: −6, 41), i.e. nearly as large
as the reduction observed in users with over 10 years of use (26% reduction) (Table 5).
Large heterogeneity in the long duration category was caused by a single study (Florida),
and after removing it, the combined estimate of 10? years NSAID use was stronger, with
lung cancer risk 43% lower (95% CI: 23, 58). Male NSAID users who took at least 7 pills
per week (i.e. usually daily) had a similar reduction in risk to men who took fewer than 7
pills per week. Amongst women, associations of NSAID use by duration or pills per week
were close to the null value of no effect (RRs in Table 5).
Other than effect modification by sex upon which all previous results have been based,
further effect modifiers of the NSAID-lung cancer association were examined separately
within each sex. Amongst men, the inverse association was stronger at younger than older
ages (RR = 0.63 under 65 years, RR = 0.91 over 65 years, Table 5); a slightly weaker
association was observed when restricting to male non-asthmatics amongst the 4 studies
with asthma history information (RR = 0.85); the association was stronger in current
smokers (RR = 0.58) than in ex-smokers (RR = 0.72, data not shown) and was not present in
never smokers (RR = 1.07, Table 5), the latter category having the smallest number of cases.
Amongst male current- and ex-smokers combined, the effect was stronger for squamous-cell
carcinomas (RR = 0.65 (95% CI: 0.44, 0.95)) than adenocarcinomas (RR 0.83 (95% CI:
0.63, 1.10)) of the lung. In women, the overall null association held in subsets defined by
smoking status and for lung cancer risk by histology.
In 4 studies (Hawaii, NELCS, AHFTS and DDCHS), there were also data on acetaminophen
use. In these 4 studies, past NSAID was inversely associated with lung cancer risk in men
(RR 0.79, 95% CI: 0.67, 0.93) whilst past acetaminophen use not (RR = 1.11, 95% CI: 0.92,
1.33). In women, neither ever-NSAID use (RR 1.00, 95% CI: 0.85, 1.17) nor ever
acetaminophen use (RR = 1.02, 95% CI: 0.87, 1.20) were associated with lung cancer risk.
Discussion
Pooled data from the ILCCO studies suggest that NSAID use is protective against lung
cancer in men, with an average risk reduction of 26% (95% CI: 8 to 41). This inverse
association was slightly stronger in current smokers and former smokers than in never
smokers, and it was also slightly stronger for squamous-cell and small-cell lung cancers than
for adenocarcinomas. Amongst men, we found that aspirin and non-aspirin NSAID use were
associated with a similar reduction in risk, but use of the latter was less common, and thus,
confidence intervals were wider. That a risk reduction was restricted to NSAID use and not
acetaminophens, another pain reliever, suggests that lung cancer risk factors associated with
use of pain relief in general and that were not controlled for did not influence the results
(although there remains the possibility of confounding by other factors) and suggests that
recall bias did not account for the association because any misclassification in the recall of
pain relief use is not expected to have differed by type of pain relief (NSAID or other).
Reverse causality is also unlikely to explain an inverse association as, if anything, recent use
of pain relief would be expected to be higher in cases in the period before diagnosis, and not
lower as observed. If asthma, a contraindication for the use of NSAIDs, was a risk factor for
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lung cancer, as is under-debate, there would be the possibility that the effect in men is partly
confounded; however, an inverse association was observed in non-asthmatic men.
The overall findings for men are consistent and of a similar magnitude to previously
reported protective effects—our estimate of a 24% reduction for NSAID use is similar to
that found in RCTs of aspirin, i.e. a 29% reduction in lung cancer mortality associated with
long-term aspirin use in Rothwell et al's pooled analysis and a 36% reduction in British
doctors [24, 25]. Khuder's meta-analysis also reported a similar reduction for aspirin of 32%
(95% CI: 15, 45) for both sexes combined, but with no differences according to sex. We
observed suggestions, although not strong, of a greater reduction the longer the duration of
NSAID use, but no dose–response effect for number of tablets per day. These analyses were
likely to be influenced by random variation, having only 1,200 cases with data on NSAID
use and the number of tablets per day not the best indicator of dose. The protective effect in
men was similar for both aspirin and non-aspirin NSAIDs. Previous studies have found
conflicting results—notably a UK study with reliable prescription data found a protective
effect only for non-aspirin NSAIDs and not for aspirin, except within a subgroup of patients
with a history of angina or myocardial infarction [26]. Their lack of association for aspirin
may be partly explained by residual confounding by smoking, which was unlikely to be a
problem in the present study.
The stronger association for squamous-cell carcinoma than for adenocarcinoma is in contrast
to what we expected and to findings in a recent prospective study [27], as adenocarcinomas
have the greatest expression of COX-2 compared to other histologies [28, 29]. Alternatively,
stronger effects for squamous-cell carcinomas and for current/former smokers may be
explained by the raised proliferative activity in their tumours, as measured by Ki-67
labelling index [30], that COX inhibitors have been shown to reduce in current and former
smokers [31].
In contrast, we observed no association between NSAID use as reported by women and lung
cancer risk, neither overall nor in any subgroup. These sex differences were not explained
by differences in type of NSAID used (aspirin or not). Data on duration, dose and reasons
for use were limited to a few studies, and thus, there was a lack of power to thoroughly
investigate these reasons for the sex difference. One possibility that may contribute, but
needs further exploration, is that, as the reasons for taking NSAIDs differ between men and
women, with women less likely to be prescribed for cardioprotection and more likely for
inflammatory conditions (arthralgia, arthritis, joint pain), types, durations, doses and
frequency of use (e.g. intermittent for menstrual pain) may differ. Alternatively true sex
differences may exist, modified by estradiol's effect on COX activity in women [32].
Previous studies have conflicting results. A similar result of a protective effect in men but
none in women was found in the prospective VITAL study [33], and no clear protective
effect was seen in the Nurses' Health Study [34]. In the Women's Health Study RCT of 100
mg aspirin every other day, followed for 10 years, lung cancer was the only cancer site with
a suggestion of reduced incidence (RR 0.78 (95% CI: 0.59, 1.03)), which was statistically
significant for lung cancer mortality (RR 0.70 (95% CI: 0.50, 0.99)) and was stronger for
small-cell than non-small-cell lung cancers (NSCLC) [35]. A protective effect on NSCLC in
Caucasian and African American women was found in Detroit [36], and with Rothwell's
pooled analysis that found an effect on overall cancer mortality in women [37].
The pooling of data from 8 studies offered several strengths. Firstly, with over 2,000 cases
in each sex, we had increased power to detect associations than in any single study (we had
92% power to detect an odds ratio of 0.8, with 35% NSAID use). Observing a consistent
association across studies and countries provides additional robustness to the findings. Our
results benefit from being based predominantly in community settings, in which NSAID use
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is at levels taken by the general population, rather than in trial settings where participants
may be more motivated to participate and adhere to allocated intervention arms. Where
hospital controls were included, this group only provided an appropriate comparison group
if NSAID use in this sample was representative of that in the general population, an
assumption that may not hold and would falsely bias results towards an apparent protective
effect of NSAIDs if there were an overrepresentation of controls with conditions for which
NSAIDs are prescribed. We excluded hospital controls admitted due to conditions for which
NSAIDs are prescribed in an attempt to obtain a control group whose prior NSAID use was
more representative of the general population. As users of NSAIDs often differ from non-
users in other risk factors for lung cancer, the ability to control for them is crucial in
observational studies. With detailed smoking data, we were able to do this for smoking, a
negative confounder. In adjusting for smoking as a confounder, because initiation of
smoking was prior to NSAID use (90% of smokers had started smoking by age 25 whereas
mean age at first NSAID use was 51 years (where data were available), it was considered as
a confounder (smokers more likely to later take NSAIDs)). However, for subjects who
changed their smoking status from current to former, it is possible that this occurred as a
result of NSAID prescription (both part of healthy behaviour advice) and thus that quitting
smoking (at an average age of 53 years) would be a downstream variable and should not be
controlled for. Potential weaknesses of our analyses include possible differential recall
between cases and controls, but whether cases have a greater or lesser tendency to report
NSAID use is unclear, and if this tendency was greater, it would have resulted in an
underestimation of the effect. Although exposure status was based on recalled self-reports,
we think it is unlikely to have been measured with more error in women, so this would not
account for sex differences. Further, prevalence of ever-NSAID use was consistent with
NHANES estimates during the periods when the studies were conducted with the exception
of higher rates in the MSKCC and Boston. Details of NSAID use varied across studies. In
particular, we have not been able to conduct a thorough investigation of the effects of age at
use, dosage, or time since last use.
If NSAIDs are protective against lung cancer, the preventive potential is attractive,
especially for aspirin given its protective effect on several other common chronic diseases
including colon cancer and cardiovascular disease [38, 39]. Smokers who take aspirin would
have a large absolute benefit for these combined endpoints, but amongst this group, the lung
cancer risk reduction associated with aspirin is small in comparison to that that could be
attained by quitting smoking [40]. Further, the adverse side effects of possible
gastrointestinal bleeding or aspirin-induced development of asthma cannot be overlooked.
Our results are consistent with a protective effect of NSAIDs, most of which were aspirin,
on lung cancer in men. Confirmation of the association of aspirin and NSA-IDs on lung
cancer is still needed, and RCTs specifically designed with cancer as the endpoint and
conducted within the general population are needed. These would clarify outstanding
questions as recently outlined in a review by Cuzick et al. including effects by lung cancer
histology, potential effect modification by sex and by smoking status, issues of safe doses,
age at use, duration of use and other potential modifying factors [41].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Effect of ever-NSAID use adjusted for age, smoking status, packyears, calendar year,
education and ethnicity, by sex
McCormack et al. Page 13










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































McCormack et al. Page 15
Table 2
Demographic and histological characteristics of included cases and non-cases
Cases Non-cases/controlsa
Studies except DDCHS DDCHS
N = 4,309 N = 2,905 N = 55,396
N (%) N (%) N (%)
Age (years)
 Mean (SD) 64.5 (9.5) 61.9 (10.8) 56.1 (4.4)c
Sex
 Male 2,227 (51.7) 1,584 (54.5) 26,392 (47.6)
 Female 2,082 (48.3) 1,321 (45.5) 29,004 (52.4)
Educational level
 Low 862 (24.8) 550 (20.1) 12,255 (22.2)
 Medium 1,683 (48.4) 1,191 (43.6) 33,038 (59.8)
 High 935 (26.9) 993 (36.3) 9,917 (18.0)
Ethnicity
 Caucasian 3,689 (85.6) 2,289 (78.8) 55,396 (100%)
 Hispanic/Latino 65 (1.5) 78 (2.7)
 Black 122 (2.8) 154 (5.3) –
 Asian 248 (5.8) 223 (7.7) –
 Native America 15 (0.4) 4 (0.1) –
 Hawaiian 160 (3.7) 147 (5.1) –
 Other 10 (0.2) 10 (0.3) –
Smoking distribution
 Never 652 (15.1) 1,100 (37.9) 19,649 (35.5)
 Ex 1,566 (36.1) 1,218 (41.9) 14,560 (26.3)
 Current 2,101 (48.8) 587 (20.2) 21,187 (38.3)
Histologyb
 Adenocarcinoma 1,674 (45.4) NA NA
 Squamous-cell carcinoma 799 (21.7)
 Large cell carcinoma 125 (3.4)
 Other non-small cell 678 (18.4)
 Small cell 410 (11.1)
a
Non-cases split by DDCHS inclusion/exclusion as 95% of non-cases are from this study
b
Distribution amongst non-missing histology. Missing for 2.5% of cases (N = 96)
c
Age at baseline questionnaire
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